Articles by Amy Ritter, PhD - BioPharm International



Articles by Amy Ritter, PhD

Amy Ritter, PhD

Scientific Editor, BioPharm International

Translating Stem Cells From Laboratory to Clinic
April 1, 2013

Ontario-area scientists discuss approaches to development of stem-cell therapies.

Lilly Discontinues Phase III Rheumatoid Arthritis Program
February 12, 2013

Eli Lilly and Co. announced that it will discontinue its Phase III rheumatoid arthritis program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, because of lack of efficacy.

FDA Lists Guidance Documents Planned for 2013
February 5, 2013

FDA has released a list of more than 50 guidance documents planned for 2013.

Ben Venue Laboratories Enters Consent Decree
January 29, 2013

Ben Venue Laboratories announced that it has voluntarily entered into a consent decree with FDA over violations of cGMP.

FTC Reports an Increase in Anticompetitive Activities Among Drug Makers
January 22, 2013

According to the Federal Trade Commission, the number of potentially anticompetitive patent dispute settlements between branded and generic drug companies increased between 2011 and 2012.

Lonza Expands Antibody-Drug Conjugate Manufacturing Capacity
January 15, 2013

Lonza will invest CHF 14 million ($15.1 million) to double the existing large-scale manufacturing capacity in Visp, Switzerland.

AbbVie Celebrates Official Launch
January 7, 2013

AbbVie, a research-focused, specialty biopharmaceutical company that was spun off from Abbott Pharmaceuticals, was officially launched on Jan. 2, 2013.

Amgen Settles False Claims Act Allegations
December 31, 2012

Amgen has agreed to pay $762 million to resolve criminal liability and false claims act allegations.

FDA Approves First Anthrax Antitoxin
December 24, 2012

Anthrax antitoxin is the first monoclonal antibody approved under FDA's Animal Efficacy Rule, and the first product from BARDA's Project Bioshield to receive FDA approval.



Click here